8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 2, 2007

MedQuist Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

New Jersey	0-19941	22-2531298
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
1000 Bishops Gate Boulevard, Suite 300, Mount Laurel, New Jersey		08054-4632
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 856.206.4000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On November 2, 2007, MedQuist Inc. (the "Company") issued a press release announcing that its Board of Directors, in connection with its previously-disclosed review of strategic alternatives, is evaluating whether a sale of the Company is in the best interests of the Company and its shareholders. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Reference is made to the Exhibit Index annexed hereto and made a part hereof.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation that the Company's evaluation of whether a sale of the Company is in the best interest of the Company and its shareholders may not result in a sale of the Company, and that any potential sale transaction reviewed by the Company may not be attractive to shareholders and may not result in enhanced shareholder value. Actual outcomes and results may differ materially from what is expressed or forecasted in forward- looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwis e.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MedQuist Inc.
November 2, 2007	By:	Mark R. Sullivan
		Name: Mark R. Sullivan
		Title: General Counsel, Chief Compliance Officer and Secretary

Exhibit Index

Exhibit No.	Description
99.1	Press release dated November 2, 2007

EX-99.1

MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders

MT. LAUREL, N.J.—(BUSINESS WIRE)—November 2, 2007—MedQuist Inc. (Pink Sheets: MEDQ.PK) announces that its Board of Directors, in connection with its previously-disclosed review of strategic alternatives for the Company, is evaluating whether a sale of the Company is in the best interests of the Company and its shareholders, in light of the announcement earlier today by Koninklijke Philips Electronics N.V. (“Philips”) of its decision to proceed with the sale of its 70% ownership interest in the Company if a satisfactory price and other acceptable terms can be realized. There is no assurance that any sale transaction will occur as a result of the evaluation.

About MedQuist:

MedQuist is a leading provider of clinical documentation workflow solutions in support of the electronic health record. MedQuist provides electronic medical transcription, health information and document management products and services, including digital dictation, speech recognition, Web- based transcription, electronic signature, medical coding, mobile dictation devices, and outsourcing services.

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist’s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties, including without limitation that the Company’s evaluation of whether a sale of the Company is in the best interest of the Company and its shareholders may not result in a sale of the Company, and that any potential sale transaction reviewed by the Company may not be attractive to shareholders and may not result in enhanced shareholder value. Actual outcomes and results may differ materially from what is expressed or forecasted in forward- looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE MedQuist Inc.
11/02/2007
CONTACT: Kathleen Donovan, Chief Financial Officer of MedQuist Inc.
+1-856-206-4000